Dr Lal Pathlabs
Vijaya Diagnostic Centre IPO opens next week; check grey market premium, price band, lot size, bid details
Vijaya Diagnostic Centre Rs 1,895-crore IPO will open for subscription on 1 September, at a price band of Rs 522-531 per share of the face value of Re 1, each.
Vijaya Diagnostic Centre IPO opens September 1; issue entirely an OFS
Vijaya Diagnostic Centre IPO will open for subscription on 1 September 2021 and close on 3 September.
Krsnaa Diagnostics IPO share allotment: Check status online, grey market premium, listing day strategy
Krsnaa Diagnostics, whose IPO saw 64.40 times subscription, is likely to finalise the share allotment on Thursday, 12 August 2021.
Analyst Corner: ‘Hold’ on Dr Lal Pathlabs with DCF-based target price of Rs 3,405
However, considering recent rally in the stock price which has made valuations fair, we downgrade it to HOLD from Add.
Krsnaa Diagnostics IPO opens August 4; check price band, grey market premium, IPO size, listing date
Krsnaa Diagnostics Rs 1,213-crore IPO will open for subscription on Wednesday, 4 August 2021, at a price band of Rs 933-954 per share of face value of Rs 5 each.
‘To reach 2.5% of GDP spend, healthcare sector does not need a gradual but a quantum jump’
On the slow pace of vaccination Mishra did mention supply bottlenecks, vaccine hesitancy & ability to reach the arm as the primary reasons but at the same time sounded optimistic that if we become more methodical, India has t
Krsnaa Diagnostics files IPO papers with Sebi; firm receives heavy demand for PCR testing amid COVID-19
Krsnaa Diagnostics filed draft papers with the market regulator Securities and Exchange Board of India (Sebi) for an initial public offering (IPO)
Technical stock picks for 2021: Buy these 7 shares; charts signal as high as 30% rally next year
Over the past four decades, global equities have always generated positive returns in a year following US elections, wherein BSE Sensex gained an average 37 per cent
Top stocks to buy post SEBI ruling: 5 high conviction midcap stocks with strong fundamentals, growth potential
The brokerage firm has prepared a basket of five high conviction midcap stocks which are fundamentally sound with good growth potential, with an equal weightage of 20 per cent.
Dr Lal PathLabs shares gain today on expansion plans; up 80% since listing
Dr Lal PathLabs shares jumped over 2 per cent in the early trade on Friday on reports that the diagnostic services provider is planning to expand its footprint across India.
Muthoot Finance, Jubilant FoodWorks among 10 stocks that remained in focus in Monday’s trade
Muthoot Finance shares closed 8.72 per cent up at Rs 233.85 after the company reported 60.56 per cent rise in net profit figures at Rs 265.22 crore for the quarter ended March 31, 2016.
Dr Lal PathLabs to acquire Delta Ria and Pathology
Diagnostic chain Dr Lal PathLabs today said it will fully acquire Delta Ria and Pathology while increasing its stake in group firms Paliwal Diagnostics and Paliwal Medicare by 10 per cent each.
Dr Lal PathLabs Q4 net profit up 20 pct at Rs 34.44 crore
Diagnostic chain Dr Lal PathLabs today reported 19.79 per cent rise in consolidated net profit at Rs 34.44 crore for the quarter ended March 31, 2016.
Dr Lal, Alkem shares extend gains for second day after blockbuster listing
Share price of diagnostic chain Dr Lal PathLabs and drug major Alkem Laboratories surged 8.43 per cent and 10.16 per cent to Rs 893.65 and Rs 1521.75, respectively on Thursday.(Photo: Reuters)
Alone and loving it: Lal Pathlabs and five other stock singles
After the success of Dr Lal Pathlabs, we take a look at some companies which are the only listed ones in their category.
Dr Lal PathLabs surges 52%, Alkem Labs gains 31% on market debut
Alkem Laboratories shares opened 31.42 per cent up from its issue price of Rs 1,050 on BSE. Dr Lal Pathlabs opened 30.36 per cent up from its issue price of Rs 550.
After Alkem and Dr Lal IPOs, Narayana Hrudayalaya set to hit market next week
Narayana Hrudayalaya is set to hit Dalal Street with its initial public offer (IPO) on December 17.
IPOs of Dr Lal PathLabs, Alkem fully subscribed
Despite volatility in the secondary markets, initial public offerings (IPO) of Alkem Laboratories and Dr Lal PathLabs managed to get fully subscribed on the second day of the three-day issue.
Dr Lal PathLabs subscribed 0.65 times
The initial public offering (IPO) of Dr Lal PathLabs was subscribed 0.65 times on the first day of three day offering.
Dr Lal PathLabs IPO hits market: Should you subscribe or avoid?
Dr Lal PathLabs' price band for the offer has been fixed at Rs 540-550 per share and the allotment to anchor investors has been done at the higher end.
Dr Lal PathLabs mops up Rs 191 cr in pre-IPO placement
Dr Lal PathLabs plans to raise Rs 638 crore through the issue based on the upper price band
Alkem Laboratories, Dr Lal Pathlabs IPOs hit markets; all you need to know
Dalal Street is set to witness two initial public offers (IPOs) this week from pharma and healthcare related companies - Alkem Laboratories and Dr Lal Pathlabs — on December 8.
Dr Lal PathLabs fixes IPO price band at Rs 540-550
Diagnostic chain Dr Lal PathLabs today fixed price band at Rs 540-550 for its initial public offer (IPO) which will hit the capital market on December 8.
Dr Lal PathLabs gets Sebi nod for IPO
Kotak Mahindra Capital and Citigroup Global Markets India are the book running lead managers for the IPO.
Dr Lal PathLabs plans IPO; files draft papers with Sebi
Diagnostic chain Dr Lal PathLabs is planning to go public and has filed draft papers with market regulator Sebi to raise funds through an IPO.
